EvoNext Holdings Ltd, previously Evolva Holding Ltd, is a Switzerland-based Company operating as a researcher for biotechnology. The Company develops and commercializes nature-based ingredients. The ingredients, produced by the Company, can be employed in, but not limited to, flavorings fragrancies, health ingredients, health protection and other various sectors. The objectives of the Company are as follows: develop technology platforms - combines biology with technology to produce nature-based ingredients; provide technology services- provides tailored services to clients across industries. The Company is focused on developing and increasing the return and effectiveness of the production of numerous ingredients within their portfolio.

Employees

Sector

Biotechnology & Medical Research

More about the company

30/04	EvoNext Holdings SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
21/08/25	EvoNext Holdings SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI

Market Cap	12.91M 15.95M 14.01M 12.08M 22.64M 1.51B 23.02M 155M 60M 741M 59.86M 58.58M 2.58B	P/E 2024	6.22x	P/E 2025	-8.95x
Enterprise Value	7M 8.65M 7.6M 6.56M 12.28M 820M 12.49M 84.09M 32.55M 402M 32.48M 31.78M 1.4B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	58.74%	Yield 2024 *	-	Yield 2025	-

30/04	EvoNext Holdings SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
21/08/25	EvoNext Holdings SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25/07/25	Evolva Shareholders OK Proposed Renaming to EvoNext	MT
25/07/25	Evolva Holding SA has Changed its Name to EvoNext Holdings SA	CI
23/07/25	Evolva to Not Receive Earn-out Payments from Unit's Buyer	MT
03/07/25	Evolva Directors Propose Change of Name to EvoNext	MT
04/06/25	Evolva Seeks Dialogue with Swiss Hospital Shareholders on Takeover Bid	MT
27/05/25	Evolva Offers to Buy Hospital in Switzerland	MT
21/02/25	Evolva Swings to FY24 Net Profit	MT
21/02/25	Evolva Holding SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
21/02/25	Evolva Holding SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
05/02/25	Evolva Holding: Shareholder Clearway Requests General Meeting	RE
31/12/24	Swiss Stocks Close Higher Ahead of New Year Break	MT

21/05	EvoNext : Minutes of Annual General Meeting 2026	PU
21/05	EvoNext shareholders approve all motions proposed by the Board at the Annual General Meeting 2026	EQ
29/04	EvoNext : Invitation to AGM 2026 E	PU
29/04	EvoNext : (2025 12 EvoNext Holdings SA Annual Report 2025)	PU
29/04	EvoNext Holdings SA publishes full-year report 2025	EQ

21/05	Evonext-Aktionäre stimmen an GV allen Anträgen zu
29/04	Evonext poursuit ses recherches, forte d'une assise financière solide
29/04	Evonext weist solide Kapitalbasis aus - Suche für Reverse Takeover läuft weiter
29/04	EvoNext : Einladung zur Generalversammlung 2026 DE
21/08/25	Evonext (ex-Evolva) a consumé des liquidités au premier semestre

ARPIDA Stock Swiss Exchange

Stocks

ARPN

Biotechnology & Medical Research

Valuation: ARPIDA

Latest news : ARPIDA

Analysts' recommendations: ARPIDA

Press Releases: ARPIDA

News in other languages: ARPIDA

Managers and Directors: ARPIDA

Other Biotechnology & Medical Research

Financials

Company Profile

Director	Title	Age	Since
Francesco Defila BRD	Director/Board Member	-	27/03/2025
Gianluca Ferrari CHM	Chairman	-	27/03/2025

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	+2.96%	+4.21%	-8.16%	-2.76%	43.24B
REVOLUTION MEDICINES, INC.	+2.23%	+8.26%	+323.35%	+564.22%	35.25B
BEONE MEDICINES AG	+1.59%	+4.63%	+7.23%	+54.02%	30.22B
IQVIA HOLDINGS INC.	+2.07%	-4.40%	+10.38%	-19.99%	28.01B
CELLTRION, INC.	-4.75%	-8.02%	+5.99%	+12.28%	24.08B
ASCENDIS PHARMA A/S	+4.64%	+3.20%	-	-	14.16B
MEDPACE HOLDINGS, INC.	+3.91%	+2.57%	+53.41%	+111.95%	13.01B
EUROFINS SCIENTIFIC SE	+2.77%	+4.02%	+9.61%	+15.31%	12.7B
IONIS PHARMACEUTICALS, INC.	+0.13%	+3.97%	+101.73%	+91.70%	12.54B
Average	+1.73%	+1.01%	+62.94%	+103.34%	23.69B
Weighted average by Cap.	+1.65%	+1.21%	+69.29%	+120.27%

	2024	2025
Net sales	-	-
Net income	1.04M 1.29M 1.13M 977K 1.83M 122M 1.86M 12.53M 4.85M 59.93M 4.84M 4.74M 208M	-653K -806K -708K -611K -1.14M -76.38M -1.16M -7.84M -3.03M -37.48M -3.03M -2.96M -130M
Net Debt	-6.75M -8.34M -7.33M -6.32M -11.84M -790M -12.04M -81.09M -31.39M -388M -31.32M -30.64M -1.35B	-5.91M -7.3M -6.41M -5.53M -10.36M -691M -10.53M -70.91M -27.45M -339M -27.39M -26.8M -1.18B

End-of-day quote Swiss Exchange Other stock markets
- ^CHF	-